Heart-mapping Acutus Medical kicks off $158M Nasdaq IPO

This past February, the company received an FDA clearance for a real-time, 3D heart-mapping algorithm, to help electrophysiologists diagnose and treat both constant and transient arrhythmias. (Getty Images)

The arrhythmia-focused Acutus Medical has moved forward with its IPO, with plans to raise about $158.8 million to help expand its commercial teams and complete the clinical testing of its heart-mapping catheters.

The company launched on the Nasdaq under the ticker “AFIB,” reflecting its work in atrial fibrillation. Acutus started with an offering of more than 8.8 million shares at $18 each, to more than double the $75 million it initially announced more than three weeks ago. That price rose nearly 50% after trading began, to about $26.50.

One year ago, Acutus brought in $100 million in venture capital funding through its series D round, plus $70 million in credit provided by Deerfield Management and an OrbiMed fund. With the latest IPO net proceeds, plus its existing cash and revenues, the company said in its prospectus that it expects to have enough to support both its commercial expansion and R&D activities for the next year.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

RELATED: Acutus Medical raises $170M to push it further into arrhythmia treatment

This past February, the company received an FDA clearance for a real-time, 3D heart-mapping algorithm, to help electrophysiologists diagnose and treat both constant and transient arrhythmias. 

The AcQMap system allows physicians to map the electrical activity of the heart’s chambers and perform an ablation, then re-check the cardiac tissue to confirm the effect. It also identifies regions of slow electrical conduction, or focal points causing irregular activity that can lead to an irregular heartbeat.

RELATED: Acutus secures FDA clearance for new real-time heart mapping algorithm

More recently, Acutus launched an electrophysiology collaboration with the German medical device maker Biotronik in May, to provide a portfolio of catheter-based mapping and ablation products in select markets such as Europe and Asia. 

Another of the alliance’s goals is to link a range of devices through Biotronik’s network, to help share real-time patient monitoring data following ablation procedures.

Acutus also worked with Stereotaxis to integrate its treatments with the latter’s telerobotic support. This allowed a patient to be treated with Acutus’ AcQMap system and Stereotaxis’ magnetic navigation system—consisting of two robotically controlled magnet arms placed on either side of the patient, which control a catheter with a magnet in its tip as it moves through the body. This also lets physicians and staff remain outside the procedure room, reducing radiation exposure.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.